Advancing CAR T-cell therapy in Australia: The Referral Process and Patient Journey

Research Review CPD-Accredited E-Learning Module

Begin

Advancing CAR T-cell therapy in Australia: The Referral Process and Patient Journey

This Research Review E-Learning Module is intended for Australian Health Professionals and is based on the following video presentations:

  1. CAR-T Therapy – The Referral Process, featuring Dr Adam Bryant and Associate Professor Andrea Henden
  2. CAR-T Therapy – The Patient Journey, featuring Dr Adam Bryant and Senior CAR-T cell Clinical Nurse Co-ordinator Cassie Abbott

The following E-Learning Module contains a multiple-choice quiz designed to assess your understanding of the material and provide certification for claiming CPD points.

Module Resources

  1. Video 1 – CAR-T Therapy; The Referral Process
  2. Video 2 – CAR-T Therapy; The Patient Journey
  3. Education Series; Advancing CAR T-cell therapy in Australia: collaborative approaches for relapsed/refractory large B-cell lymphoma

The videos and this E-Learning Module covers:

  • Patient selection criteria and the referral process for eligible patients with diffuse large B-cell lymphoma for CAR T-cell therapy
  • Access criteria and indications for CAR T-cell therapy in Australia
  • The treatment process
  • Procedures for monitoring side effects, post-treatment care, and follow-up after a patient receives CAR T-cell therapy
  • Factors that impact treatment outcomes including, caregiver support, geographical considerations, timely patient management, and good communication between treatment and referring centres

This E-Learning Module is simple multi-choice quiz to measure understanding of the video presentations, and to provide certification for the purposes of claiming CPD points. To achieve the level required to receive CPD certification, participants are expected to achieve a minimum of 80% of questions answered correctly. 

Learning outcomes

After completing this module you should have an improved understanding of the:

  • Importance of collaboration between referring and CAR T-cell treatment centres in managing patients with relapsed refractory diffuse large B-cell lymphoma
  • The typical patient journey through CAR T-cell therapy and the importance of early referral
  • Availability of CAR T-cell therapy and patient eligibility criteria in Australia
  • Potential complications and side effects of CAR T-cell therapy
  • Post-treatment care requirements for CAR T-cell therapy patients

Contributing experts

Video presentations were conducted by Dr Adam Bryant, Associate Professor Andrea Henden and Cassie Abbott. The questions included in this module have been reviewed by a contributing specialist.

Accreditation

RACP (Royal Australasian College of Physicians) MyCPD participants can claim the time spent completing Research Review modules as CPD in the online MyCPD program. Please contact MyCPD@racp.edu.au for any assistance. Please CLICK HERE to download CPD Information.

Nursing and Midwifery Board of Australia (NMBA) Completing e-Learning modules may be considered a self-directed activity set out in the NMBA Registration Standard: Continuing Professional Development. Nurses and midwives are required to complete a minimum number of CPD hours directly relevant to their context of practice. One hour of active learning will equal one hour of CPD. For more information go to The Nursing and Midwifery Board of Australia (NMBA) CPD page. Please CLICK HERE to download more info.

References

  1. Lymphoma Australia. Available at: https://www.lymphoma.org.au/types-of-lymphoma/non-hodgkinlymphoma/aggressive-fast-growing-b-cell-nhl/diffuse-large-b-cell-dlbcl/ (accessed August 2024).
  2. Melchardt T, Egle A, Greil R. How I treat diffuse large B-cell lymphoma. ESMO Open 2023; 8:100750.
  3. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med 2021; 384:842-858.
  4. Leick MB, Maus MV, Frigault MJ. Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Mol Ther 2021; 29:433-441.
  5. Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2014; 32:1066-73.
  6. Crees ZD, Ghobadi A. Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. Cancers (Basel) 2021; 13.
  7. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130:1800-1808.
  8. Gilead Sciences Ltd. YESCARTA® (axicabtagene ciloleucel) U.S. Prescribing Information. July 2024.
  9. Gilead Sciences Ltd. YESCARTA® (axicabtagene ciloleucel) Summary of Product Characteristics. July 2024.
  10. Novartis Pharmaceuticals UK Ltd. Kymriah® (tisagenlecleucel) Summary of Product Characteristics. September 2024.
  11. Novartis Pharmaceuticals Corporation. Kymriah® (tisagenlecleucel) US Prescribing Information. July 2024.
  12. Juno Therapeutics Inc. BREYANZI® (lisocabtagene maraleucel). U.S. Prescribing information. May 2024.
  13. Bristol-Myers Squibb Pharma EEIG. Breyanzi (lisocabtagene maraleucel) Summary of Product Characteristics. September 2024.
  14. Medical Services Advisory Committee. Public Summary Document: Application No. 1587 – Axicabtagene ciloleucel (CAR-T therapy) for the treatment of refractory or relapsed CD19-positive lymphoma. Jan 2020.
  15. Medical Services Advisory Committee. Public Summary Document: Application No. 1676 – Amendments to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma. July 2021.
  16. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017; 377:2531-2544.
  17. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380:45-56.
  18. Gajra A, Jeune-Smith Y, Kish J, Yeh TC, Hime S, Feinberg B. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma. Immunotherapy 2020; 12:725-732.
  19. Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 2023; 29:440-448.
  20. Gilead Sciences Pty Ltd. YESCARTA® (axicabtagene ciloleucel) Australian Product Information. 22 April 2024.
  21. Novartis Pharmaceuticals Australia Pty Ltd. Kymriah® (tisagenlecleucel) Australian Prescribing Information. May 2022.
  22. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019; 20:31-42.
  23. Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023; 141:2307-2315.
  24. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021; 22:1403-1415.
  25. Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 2022; 28:2145-2154.
  26. Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol 2020; 38: 3095-3106.
  27. Kwon M, Iacoboni G, Reguera JL, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica 2023; 108:110-121.
  28. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 2020; 38:3119-3128.
  29. Riedell PA, Hwang WT, Nastoupil LJ, et al. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/ Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther 2022; 28:669-676.
  30. Sermer D, Batlevi C, Palomba ML, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv 2020; 4:4669-4678.
  31. Landsburg D, Frigault M, Heim M, et al. Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin’s Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood 2022; 140:1584–1587.
  32. Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 2022; 386:629-639.
  33. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022; 399:2294-2308.
  34. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 2022; 386:640-654.
  35. Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med 2023; 389:148-157.
  36. Bishop MR, Kay GE. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists. Semin Oncol 2024; 51:87-94.
  37. Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma 2018; 59:1785-1796.
  38. Reiser V. Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications. J Adv Pract Oncol 2020; 11:159-167.
  39. Kansagra A, Farnia S, Majhail N. Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities. Am Soc Clin Oncol Educ Book 2020; 40:1-8.
  40. Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood 2018; 132:777-781.
  41. Chen AJ, Zhang J, Agarwal A, Lakdawalla DN. Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma. Value Health 2022; 25:1344-1351.
  42. Johnson PC, Abramson JS. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas. Leuk Lymphoma 2020; 61:2561-2567.
  43. Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 2020; 105:297-316.
  44. Amini L, Silbert SK, Maude SL, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 2022; 19:342-355.
  45. Granroth G, Rosenthal A, McCallen M, et al. Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective. Curr Oncol Rep 2022; 24:1863-1872.
  46. Mikhael J, Fowler J, Shah N. Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access. JCO Oncol Pract 2022; 18:800-807.
  47. Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 2023; 20:359-371.
  48. Lemoine J, Bachy E, Cartron G, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv 2023; 7:6589-6598.
‹Previous Next›